Lirafugratinib + LITESPARK011
This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA approval of the latest one, lirafugra...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
OncoPharm
Oncology Pharmacist & Educator. Talking all things #oncopharm
Episodes
20 of 445 episodesPI3K Pathway Hyperglycemia
Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well...
Neutropenic Diets & Lung Cancer Updates
This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients on treatment for cancer. Link: https...
How to Read a Press Release and Drug Shortage Help
Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from...
Paradigm and Daraxonrasib in NSCLC
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients wi...
Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates
This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic c...
Iberdomide
CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology...
Kidney Cancer in a Nutshell
Overview of renal cell carcinoma Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Small Cell Lung Cancer and CINV Updates
This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuxi...
Zidesamtinib & PPIs in Pacific
A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also,...
Gedatolisib et al
This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizum...
Endurance Part 2
Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056...
A Decade of CAR-T, Ocra-T, & POLARGO
We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved,...
Breast Cancer Updates and T-Cell Stemness
This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govi...
Updates on capivasertib, belzutifan, talquetamab, & durvalumab
Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizuma...
ASCO '26
ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ova...
Pivekimab sunirine
Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what...
BCL2 & HER2 Targeting Agent Updates
The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell L...
IMHOTEP, PJP, and more
This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https...
Vepdegestrant
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that a...